Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
2019;25:462-469) found that somatic PTEN mutations were associated with resistance to immune checkpoint inhibitors by altering immunosuppressive environments in patients with glioblastomas.
|
30928438 |
2019 |
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Glioblastomas frequently carry genetic alterations resulting in an aberrant activation of the phosphoinositol-3-kinase (Pi3k)/protein kinase B (Akt) signalling pathway, including most notably phosphatase and tensin homolog (PTEN) mutation, epidermal growth factor receptor (EGFR) amplification and rearrangement, as well as carboxyl-terminal modulator protein (CTMP) hypermethylation [Knobbe et al., (2004) Hypermethylation and transcriptional downregulation of the carboxyl-terminal modulator protein gene in glioblastomas.J Natl Cancer Institute, 96, 483-486].
|
16150119 |
2005 |
Glioblastoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Glioblastomas often show activation of epidermal growth factor receptor (EGFR) and loss of PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor, but it is not known if these two genetic lesions act together to transform cells.
|
18812521 |
2009 |
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Glioblastoma harbors frequent alterations in receptor tyrosine kinases, phosphatidylinositol‑3 kinase (PI3K) and phosphatase and tensin homolog (PTEN) that dysregulate phospholipid signaling driven tumor proliferation and therapeutic resistance.
|
30942445 |
2019 |
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
GBM tumors with concurrent EGFR amplification and active phosphatase and tensin homolog (PTEN) are sensitive to the tyrosine kinase inhibitor erlotinib, but the effect is not durable.
|
31352310 |
2019 |
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
PTEN is a candidate tumor suppressor gene identified on human chromosome 10q23.3 that is frequently mutated or deleted in 30% to 44% of glioblastomas.
|
10331435 |
1999 |
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
PTEN mutations have been implicated in the development of a variety of human neoplasia, including high-grade glioblastoma, prostate, breast, endometrial, and thyroid carcinoma.
|
10910075 |
2000 |
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
PTEN/MMAC1 (phosphatase and tensin homolog/mutated in multiple advanced cancers 1) is a tumor suppressor gene, the inactivation of which is an important step in the progression of gliomas to end-stage glioblastoma multiforme.
|
11303623 |
2000 |
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
PTEN has also been found to be somatically deleted, mutated, and/or silenced in various sporadically occurring cancers such as glioblastoma, breast cancer, kidney cancer, malignant melanoma, and endometrial cancer.
|
12203792 |
2002 |
Glioblastoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
PTEN is frequently inactivated in many tumour types including glioblastoma, prostate and endometrial cancers.
|
14724591 |
2004 |
Glioblastoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma.
|
15735028 |
2005 |
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
PTEN restoration or PIK3CB knockdown is also able to efficiently inhibit the growth of human U251 glioblastoma xenografts in nude mice, while tumor growth is entirely suppressed by a combination of the two treatments.
|
21188471 |
2011 |
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Phosphatase and tensin homolog reconstruction and vascular endothelial growth factor knockdown synergistically inhibit the growth of glioblastoma.
|
21204766 |
2010 |
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
PTEN is a tumor suppressor gene localized to human chromosome 10q23.31, a genomic region frequently lost in glioblastoma and prostate cancer.
|
21486223 |
2011 |
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Phosphatase and tensin homolog located on chromosome 10 (PTEN) is one of the most frequently mutated tumor suppressors in human cancer including in glioblastoma.
|
23908595 |
2013 |
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
PTEN, which is frequently mutated in glioblastomas, is a tumor suppressor gene that encodes a dual specificity phosphatase that antagonizes the phosphatidylinositol 3-kinase class I/AKT/mTOR pathway, which is a key regulator of autophagy.
|
24349488 |
2013 |
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) deficiency in primary human glioblastoma (GBM) is associated with increased invasiveness and poor prognosis with unknown mechanisms.
|
30357833 |
2019 |
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
PTEN mutations were detected in 9 of 36 glioblastomas (25%).
|
9426052 |
1998 |
Glioblastoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
A PTEN-COL17A1 fusion gene and its novel regulatory role in Collagen XVII expression and GBM malignance.
|
29156757 |
2017 |
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
According to the preliminary findings of this study, in addition to the EGFR gene, amplification of other genes on chromosome 7 and the deletion of PTEN gene and other cancer-related genes on chromosome 10 appeared important to the development of glioblastoma multiforme and were associated with poor prognosis, whereas the combination of chromosome 1p and 19q deletions seems to be an informative molecular marker for better prognosis.
|
12845540 |
2004 |
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Accordingly, targeting both pathways simultaneously resulted in mitotic catastrophe and tumor apoptosis and markedly reduced the growth of PTEN-deficient glioblastomas in vitro and in vivo.
|
24076665 |
2013 |
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Actin cytoskeleton organization, cell surface modification and invasion rate of 5 glioblastoma cell lines differing in PTEN and p53 status.
|
25149900 |
2015 |
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Additionally, expression and prognostic value of NMI were associated with molecular features of GBM including PTEN deletion and EGFR amplification in TCGA cohort.
|
25669971 |
2015 |
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Additive effects of the combined expression of soluble forms of GAS1 and PTEN inhibiting glioblastoma growth.
|
29941984 |
2018 |